CD38 and rheumatoid arthritis: Most importantly, for the first time, we evaluated the efficacy of a U.S. Food and Drug Administration-approved cancer drug targeting CD38, daratumumab, in depleting plasma cells/plasmablasts ex vivo in PBMC from patients with RA and SLE, to provide a rationale for clinical trials of daratumumab in patients with RA and SLE.